Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity

Igor Barjaktarevic1 Division of Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, [email protected]Correspondence[email protected]

Robert Kaner2 Division of Pulmonary and Critical Care, Weill Cornell Medicine, NY, USA;3 Department of Genetic Medicine, Weill Cornell Medicine, NY, USA

Russell G Buhr1 Division of Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, [email protected];4 Department of Health Policy and Management, Fielding School of Public Health at UCLA, Los Angeles, CA, USA

Christopher B Cooper1 Division of Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, [email protected];5 Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity

Figures & data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date